{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:45Z","timestamp":1777870365754,"version":"3.51.4"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca ITA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is a global health problem, affecting more than 850 million people worldwide. The number of patients receiving renal replacement therapy (dialysis or renal transplantation) has increased over the years, and it has been estimated that the number of people receiving renal replacement therapy will more than double from 2.618 million in 2010 to 5.439 million in 2030, with wide\u00a0differences among countries. The main focus of CKD treatment has now become preserving renal function rather than replacing it. This is possible, at least to some extent, through the optimal use of multifactorial therapy aimed at preventing end-stage kidney disease and cardiovascular events. Sodium\/glucose cotransporter 2 inhibitors (SGLT2i) reduce glomerular hypertension and albuminuria with beneficial effects on progression of renal damage in both diabetic and non-diabetic CKD. SGLT2 inhibitors also show great benefits in cardiovascular protection, irrespective of diabetes. Therefore, the use of these drugs will likely be extended to the whole CKD population as a new\u00a0standard of care.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s40620-022-01336-7","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T09:03:02Z","timestamp":1652864582000},"page":"1605-1618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?"],"prefix":"10.1093","volume":"35","author":[{"given":"Luca","family":"De Nicola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Genovesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Grandaliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"issue":"5","key":"1336_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C (2019) A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96(5):1048\u20131050. https:\/\/doi.org\/10.1016\/j.kint.2019.07.012","journal-title":"Kidney Int"},{"key":"1336_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"issue":"9981","key":"1336_CR3","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385(9981):1975\u20131982. https:\/\/doi.org\/10.1016\/S0140-6736(14)61601-9","journal-title":"Lancet"},{"issue":"3","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ekir.2019.12.003","volume":"5","author":"VA Luyckx","year":"2019","unstructured":"Luyckx VA, Cherney DZI, Bello AK (2019) Preventing CKD in developed countries [published correction appears in Kidney Int Rep 2020;5(5):758]. Kidney Int Rep 5(3):263\u2013277. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.003","journal-title":"Kidney Int Rep"},{"issue":"3","key":"1336_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH et al (2018) Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 94(3):567\u2013581. https:\/\/doi.org\/10.1016\/j.kint.2018.04.011","journal-title":"Kidney Int"},{"issue":"5","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ndt\/gfu383","volume":"30","author":"L De Nicola","year":"2015","unstructured":"De Nicola L, Donfrancesco C, Minutolo R et al (2015) Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008\u201312 National Health Examination Survey. Nephrol Dial Transplant 30(5):806\u2013814. https:\/\/doi.org\/10.1093\/ndt\/gfu383","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ndt\/gfv427","volume":"31","author":"L De Nicola","year":"2016","unstructured":"De Nicola L, Zoccali C (2016) Chronic kidney disease prevalence in the general population: heterogeneity and concerns. Nephrol Dial Transplant 31(3):331\u2013335. https:\/\/doi.org\/10.1093\/ndt\/gfv427","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1681\/ASN.V24832","volume":"2","author":"G Maschio","year":"1991","unstructured":"Maschio G, Oldrizzi L, Rugiu C (1991) Is there a \u201cpoint of no return\u201d in progressive renal disease? J Am Soc Nephrol 2(4):832\u2013840. https:\/\/doi.org\/10.1681\/ASN.V24832","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2215\/CJN.07820719","volume":"15","author":"AS Kliger","year":"2020","unstructured":"Kliger AS, Brosius FC, Diabetic Kidney Disease Task Force of the American Society of Nephrology (2020) Preserving kidney function instead of replacing it. Clin J Am Soc Nephrol 15(1):129\u2013131. https:\/\/doi.org\/10.2215\/CJN.07820719","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1523-1755.2003.t01-2-00052.x","volume":"64","author":"BM Brenner","year":"2003","unstructured":"Brenner BM (2003) Retarding the progression of renal disease. Kidney Int 64(1):370\u2013378. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.t01-2-00052.x","journal-title":"Kidney Int"},{"issue":"17","key":"1336_CR11","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108(17):2154\u20132169. https:\/\/doi.org\/10.1161\/01.CIR.0000095676.90936.80","journal-title":"Circulation"},{"issue":"10184","key":"1336_CR12","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL et al (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [published correction appears in Lancet 2019;393(10184):1936]. Lancet 393(10184):1937\u20131947. https:\/\/doi.org\/10.1016\/S0140-6736(19)30772-X","journal-title":"Lancet"},{"key":"1336_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.amjmed.2007.05.012","volume":"120","author":"TP Ryan","year":"2007","unstructured":"Ryan TP, Sloand JA, Winters PC et al (2007) Chronic kidney disease prevalence and rate of diagnosis. Am J Med 120:981\u2013986. https:\/\/doi.org\/10.1016\/j.amjmed.2007.05.012","journal-title":"Am J Med"},{"key":"1336_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/j.ajkd.2010.08.022","volume":"57","author":"M Ravera","year":"2011","unstructured":"Ravera M, Noberasco G, Weiss U et al (2011) CKD awareness and blood pressure control in the primary care hypertensive population. Am J Kidney Dis 57:71\u201377. https:\/\/doi.org\/10.1053\/j.ajkd.2010.08.022","journal-title":"Am J Kidney Dis"},{"key":"1336_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12882-019-1551-3","volume":"20","author":"CJ Diamantidis","year":"2019","unstructured":"Diamantidis CJ, Hale SL, Wang V et al (2019) Lab-based and diagnosis-based chronic kidney disease recognition and staging concordance. BMC Nephrol 20:357. https:\/\/doi.org\/10.1186\/s12882-019-1551-3","journal-title":"BMC Nephrol"},{"key":"1336_CR16","doi-asserted-by":"publisher","unstructured":"Sultan, AA, Barone S, Kumar S et al (2021) REVEAL-CKD: prevalence of and patient characteristics associated with undiagnosed stage 3 chronic kidney disease [poster]. In: Presented at ADA 81st Scientific Sessions; June 25\u201329, 2021; Virtual. Poster #998-P. https:\/\/doi.org\/10.2337\/db21-998-P","DOI":"10.2337\/db21-998-P"},{"issue":"11","key":"1336_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.amjmed.2011.04.026","volume":"124","author":"NA Smart","year":"2011","unstructured":"Smart NA, Titus TT (2011) Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med 124(11):1073-1080.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2011.04.026","journal-title":"Am J Med"},{"issue":"8","key":"1336_CR18","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/ndt\/gfl198","volume":"21","author":"C Jones","year":"2006","unstructured":"Jones C, Roderick P, Harris S, Rogerson M (2006) Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. Nephrol Dial Transplant 21(8):2133\u20132143. https:\/\/doi.org\/10.1093\/ndt\/gfl198","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1336_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2215\/CJN.10481013","volume":"9","author":"R Minutolo","year":"2014","unstructured":"Minutolo R, Lapi F, Chiodini P et al (2014) Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol 9(9):1586\u20131593. https:\/\/doi.org\/10.2215\/CJN.10481013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"1336_CR20","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2215\/CJN.01180211","volume":"6","author":"L De Nicola","year":"2011","unstructured":"De Nicola L, Chiodini P, Zoccali C et al (2011) Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 6(10):2421\u20132428. https:\/\/doi.org\/10.2215\/CJN.01180211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1336_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40620-018-00570-2","volume":"32","author":"A Santoro","year":"2019","unstructured":"Santoro A, Gibertoni D, Rucci P et al (2019) The PIRP project (Prevenzione Insufficienza Renale Progressiva): how to integrate hospital and community maintenance treatment for chronic kidney disease. J Nephrol 32(3):417\u2013427. https:\/\/doi.org\/10.1007\/s40620-018-00570-2","journal-title":"J Nephrol"},{"issue":"6","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40620-020-00820-2","volume":"33","author":"D de Zeeuw","year":"2020","unstructured":"de Zeeuw D (2020) The future of Diabetic Kidney Disease management: reducing the unmet need. J Nephrol 33(6):1163\u20131169. https:\/\/doi.org\/10.1007\/s40620-020-00820-2","journal-title":"J Nephrol"},{"issue":"5","key":"1336_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V et al (2016) Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67(5):728\u2013741. https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.011","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1336_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1681\/ASN.2018100971","volume":"30","author":"DP Murphy","year":"2019","unstructured":"Murphy DP, Drawz PE, Foley RN (2019) Trends in angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use among those with impaired kidney function in the United States. J Am Soc Nephrol 30(7):1314\u20131321. https:\/\/doi.org\/10.1681\/ASN.2018100971","journal-title":"J Am Soc Nephrol"},{"issue":"4S","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4S):S1\u2013S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019","journal-title":"Kidney Int"},{"key":"1336_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.08720816","volume":"12","author":"L Manns","year":"2017","unstructured":"Manns L, Scott-Douglas N, Tonelli M et al (2017) A population-based analysis of quality indicators in CKD. Clin J Am Soc Nephrol 12:727\u2013733. https:\/\/doi.org\/10.2215\/CJN.08720816","journal-title":"Clin J Am Soc Nephrol"},{"key":"1336_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH et al (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580\u2013591. https:\/\/doi.org\/10.1056\/NEJMoa0706245","journal-title":"N Engl J Med"},{"key":"1336_CR28","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2021) Kidney disease statistics for the United States. NIDDK. https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/kidney-disease"},{"issue":"3","key":"1336_CR29","doi-asserted-by":"publisher","first-page":"e0230512","DOI":"10.1371\/journal.pone.0230512","volume":"15","author":"S Elshahat","year":"2020","unstructured":"Elshahat S, Cockwell P, Maxwell AP, Griffin M, O\u2019Brien T, O\u2019Neill C (2020) The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS ONE 15(3):e0230512. https:\/\/doi.org\/10.1371\/journal.pone.0230512","journal-title":"PLoS ONE"},{"issue":"5","key":"1336_CR30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1365-2796.2010.02269.x","volume":"268","author":"P Stenvinkel","year":"2010","unstructured":"Stenvinkel P (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 268(5):456\u2013467. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02269.x","journal-title":"J Intern Med"},{"issue":"13","key":"1336_CR31","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [published correction appears in N Engl J Med 2008;18(4):4]. N Engl J Med 351(13):1296\u20131305. https:\/\/doi.org\/10.1056\/NEJMoa041031","journal-title":"N Engl J Med"},{"issue":"9854","key":"1336_CR32","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox CS, Matsushita K, Woodward M et al (2012) Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [published correction appears in Lancet 2013;381(9864):374]. Lancet 380(9854):1662\u20131673. https:\/\/doi.org\/10.1016\/S0140-6736(12)61350-6","journal-title":"Lancet"},{"issue":"8","key":"1336_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.7326\/0003-4819-157-8-201210160-00533","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer VA, U.S. Preventive Services Task Force (2012) Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157(8):567\u2013570. https:\/\/doi.org\/10.7326\/0003-4819-157-8-201210160-00533","journal-title":"Ann Intern Med"},{"issue":"4","key":"1336_CR34","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"1336_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ckj\/sfw044","volume":"9","author":"RM Perkins","year":"2016","unstructured":"Perkins RM, Chang AR, Wood KE, Coresh J, Matsushita K, Grams M (2016) Incident chronic kidney disease: trends in management and outcomes. Clin Kidney J 9(3):432\u2013437. https:\/\/doi.org\/10.1093\/ckj\/sfw044","journal-title":"Clin Kidney J"},{"issue":"6","key":"1336_CR36","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67(6):2089\u20132100. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00365.x","journal-title":"Kidney Int"},{"key":"1336_CR37","unstructured":"Stevens L, Perrone RD (2008) Drugs that elevate the serum creatinine concentration. UpToDate online. http:\/\/uptodateonline.com\/online\/content\/topic.do?topicKey=fldlytes\/32725&selectedTitle=2~150&source=search_result. Accessed 17 Dec 2008"},{"issue":"2","key":"1336_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0025-6196(11)60826-4","volume":"84","author":"NM Paige","year":"2009","unstructured":"Paige NM, Nagami GT (2009) The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc 84(2):180\u2013186. https:\/\/doi.org\/10.1016\/S0025-6196(11)60826-4","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"1336_CR39","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1681\/ASN.2005050496","volume":"16","author":"GS Markowitz","year":"2005","unstructured":"Markowitz GS, Stokes MB, Radhakrishnan J, D\u2019Agati VD (2005) Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 16(11):3389\u20133396. https:\/\/doi.org\/10.1681\/ASN.2005050496","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1336_CR40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC et al (2021) Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):559\u2013569. https:\/\/doi.org\/10.1016\/j.kint.2020.10.026","journal-title":"Kidney Int"},{"issue":"3","key":"1336_CR41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","volume":"67","author":"G Wolf","year":"2005","unstructured":"Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67(3):799\u2013812. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00145.x","journal-title":"Kidney Int"},{"key":"1336_CR42","unstructured":"National Kidney Foundation (2008) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, part 7: stratification of risk for progression of kidney disease and development of cardiovascular disease guideline 13. Factors associated with loss of kidney function in chronic kidney disease. http:\/\/kidneyfoundation.cachefly.net\/professionals\/KDOQI\/guidelines_ckd\/p7_risk_g13.htm. Accessed 17 Dec 2008"},{"issue":"1","key":"1336_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148(1):30\u201348. https:\/\/doi.org\/10.7326\/0003-4819-148-1-200801010-00190","journal-title":"Ann Intern Med"},{"issue":"10302","key":"1336_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V (2021) Chronic kidney disease. Lancet 398(10302):786\u2013802. https:\/\/doi.org\/10.1016\/S0140-6736(21)00519-5","journal-title":"Lancet"},{"issue":"20","key":"1336_CR45","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T (1998) Pathophysiology of progressive nephropathies. N Engl J Med 339(20):1448\u20131456. https:\/\/doi.org\/10.1056\/NEJM199811123392007","journal-title":"N Engl J Med"},{"issue":"1","key":"1336_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ki.1997.2","volume":"51","author":"G Remuzzi","year":"1997","unstructured":"Remuzzi G, Ruggenenti P, Benigni A (1997) Understanding the nature of renal disease progression. Kidney Int 51(1):2\u201315. https:\/\/doi.org\/10.1038\/ki.1997.2","journal-title":"Kidney Int"},{"issue":"7","key":"1336_CR47","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.3390\/jcm9072243","volume":"9","author":"L De Nicola","year":"2020","unstructured":"De Nicola L, Gabbai FB, Garofalo C, Conte G, Minutolo R (2020) Nephroprotection by SGLT2 inhibition: back to the future? J Clin Med 9(7):2243. https:\/\/doi.org\/10.3390\/jcm9072243 (Published 2020 Jul 15)","journal-title":"J Clin Med"},{"issue":"8","key":"1336_CR48","doi-asserted-by":"publisher","first-page":"bqab 079","DOI":"10.1210\/endocr\/bqab079","volume":"162","author":"CWS Hoong","year":"2021","unstructured":"Hoong CWS (2021) Chua MWJ (2021) SGLT2 inhibitors as calorie restriction-mimetics: insights on longevity pathways and age-related diseases. Endocrinology 162(8):bqab 079. https:\/\/doi.org\/10.1210\/endocr\/bqab079","journal-title":"Endocrinology"},{"issue":"2","key":"1336_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.17925\/EE.2018.14.2.40","volume":"14","author":"DH Fitchett","year":"2018","unstructured":"Fitchett DH (2018) Empagliflozin and cardio-renal outcomes in patients with type 2 diabetes and cardiovascular disease\u2014implications for clinical practice. Eur Endocrinol 14(2):40\u201349. https:\/\/doi.org\/10.17925\/EE.2018.14.2.40","journal-title":"Eur Endocrinol"},{"issue":"1","key":"1336_CR50","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH et al (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11(1):2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"issue":"12","key":"1336_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11892-020-01359-z","volume":"20","author":"P Ekanayake","year":"2020","unstructured":"Ekanayake P, Hupfeld C, Mudaliar S (2020) Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors and ketogenesis: the good and the bad. Curr Diab Rep 20(12):74. https:\/\/doi.org\/10.1007\/s11892-020-01359-z","journal-title":"Curr Diab Rep"},{"issue":"8","key":"1336_CR52","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2337\/db20-1045","volume":"70","author":"M Albiero","year":"2021","unstructured":"Albiero M, Tedesco S, Amendolagine FI et al (2021) (2021) Inhibition of SGLT-2 rescues bone marrow cell traffic for vascular repair. Role of glucose control and ketogenesis. Diabetes 70(8):1767\u20131779. https:\/\/doi.org\/10.2337\/db20-1045","journal-title":"Diabetes"},{"issue":"11","key":"1336_CR53","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM et al (2021) Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(11):755\u2013766. https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"1336_CR54","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","volume":"81","author":"L Del Vecchio","year":"2021","unstructured":"Del Vecchio L, Beretta A, Jovane C, Peiti S, Genovesi S (2021) A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease. Drugs 81(13):1491\u20131511. https:\/\/doi.org\/10.1007\/s40265-021-01573-3","journal-title":"Drugs"},{"issue":"24","key":"1336_CR55","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"1336_CR56","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK (2020) VERTIS CV Investigators: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435","journal-title":"N Engl J Med"},{"issue":"4","key":"1336_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"7","key":"1336_CR58","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jamacardio.2021.0660","volume":"6","author":"TA Zelniker","year":"2021","unstructured":"Zelniker TA, Raz I, Mosenzon O et al (2021) Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. JAMA Cardiol 6(7):801\u2013810. https:\/\/doi.org\/10.1001\/jamacardio.2021.0660","journal-title":"JAMA Cardiol"},{"issue":"15","key":"1336_CR59","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"issue":"21","key":"1336_CR60","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"2","key":"1336_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"issue":"15","key":"1336_CR62","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"1","key":"1336_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(1):22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1336_CR64","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","volume":"32","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Vart P, Jongs N et al (2021) Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol 32(9):2352\u20132361. https:\/\/doi.org\/10.1681\/ASN.2021020167","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"1336_CR65","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"issue":"16","key":"1336_CR66","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990\u20132010. N Engl J Med 370(16):1514\u20131523. https:\/\/doi.org\/10.1056\/NEJMoa1310799","journal-title":"N Engl J Med"},{"issue":"5","key":"1336_CR67","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40620-020-00803-3","volume":"33","author":"G Leoncini","year":"2020","unstructured":"Leoncini G, Viazzi F, De Cosmo S et al (2020) Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol 33(5):949\u2013963. https:\/\/doi.org\/10.1007\/s40620-020-00803-3","journal-title":"J Nephrol"},{"issue":"11","key":"1336_CR68","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/jch.13396","volume":"20","author":"F Viazzi","year":"2018","unstructured":"Viazzi F, Leoncini G, Grassi G, Pontremoli R (2018) Antihypertensive treatment and renal protection: Is there a J-curve relationship? J Clin Hypertens (Greenwich) 20(11):1560\u20131574. https:\/\/doi.org\/10.1111\/jch.13396","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"22","key":"1336_CR69","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"1336_CR70","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"1","key":"1336_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-019-0822-4","volume":"18","author":"O Schnell","year":"2019","unstructured":"Schnell O, Standl E, Catrinoiu D et al (2019) Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol 18(1):30. https:\/\/doi.org\/10.1186\/s12933-019-0822-4","journal-title":"Cardiovasc Diabetol"},{"key":"1336_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00295-3","author":"P Rossing","year":"2022","unstructured":"Rossing P, Inzucchi SE, Vart P, for the DAPA-CKD and DAPA-HF Trial Committees and Investigators et al (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(21)00295-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1336_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.622593","volume":"7","author":"A Cupisti","year":"2020","unstructured":"Cupisti A, Giannese D, Moriconi D et al (2020) Nephroprotection by SGLT2i in CKD patients: may it be modulated by low-protein plant-based diets? Front Med (Lausanne) 7:622593. https:\/\/doi.org\/10.3389\/fmed.2020.622593","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"1336_CR74","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/dom.14071","volume":"22","author":"M Mazzucato","year":"2020","unstructured":"Mazzucato M, Fioretto P, Avogaro A (2020) High-protein diet: a barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors? Diabetes Obes Metab 22(9):1511\u20131515. https:\/\/doi.org\/10.1111\/dom.14071","journal-title":"Diabetes Obes Metab"},{"key":"1336_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac046","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Jardine MJ (2022) SGLT2 inhibitors and finerenone: one or the other or both? Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfac046 (Online ahead of print)","journal-title":"Nephrol Dial Transplant"},{"key":"1336_CR76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","volume":"99","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Kohan DE, de Zeeuw D (2021) New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int 99:346\u2013349. https:\/\/doi.org\/10.1016\/j.kint.2020.09.026","journal-title":"Kidney Int"},{"issue":"2","key":"1336_CR77","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41581-021-00522-3","volume":"18","author":"P Fioretto","year":"2022","unstructured":"Fioretto P, Pontremoli R (2022) Expanding the therapy options for diabetic kidney disease. Nat Rev Nephrol 18(2):78\u201379","journal-title":"Nat Rev Nephrol"},{"key":"1336_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab336","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Anker SD, Filippatos G et al (2021) Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfab336","journal-title":"Nephrol Dial Transplant"},{"key":"1336_CR79","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Filippatos G, Agarwal R et al (2022) Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep 7:36\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2021.10.008","journal-title":"Kidney Int Rep"},{"issue":"2","key":"1336_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 41(2):255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"issue":"Supplement 4","key":"1336_CR81","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(Supplement 4):S1\u2013S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019","journal-title":"Kidney Int"},{"issue":"Suppl. 1","key":"1336_CR82","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association (2022) Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl. 1):S125\u2013S143. https:\/\/doi.org\/10.2337\/dc22-S009","journal-title":"Diabetes Care"},{"issue":"1","key":"1336_CR83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS et al (2020) Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol 19(1):185. https:\/\/doi.org\/10.1186\/s12933-020-01154-w","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01336-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:51Z","timestamp":1777564491000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/6\/1605\/8325744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":83,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01336-7","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"12 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MC has served as a Lecturer for AstraZeneca; LDN has served as a consultant and\/or lecturer for Astellas, AstraZeneca, Mundipharma, Novo Nordisk; SG has received speaker fees from Astra Zeneca, Boehringer-Ingelheim; LG has provided research support for Abionyx, Sanofi, has served as a speaker for Fresenius, Estor, Werfen, Astellas, AstraZeneca, Travere and as a consultant for Sandoz, Sanofi, Baxter, Mundipharma, Estor, Pharmadoc, Retrophin, Travere, AstraZeneca, GSK, Novartis, Chinook; GG has no conflict of interests; RP has received speaker fees from Astra Zeneca, Boehringer-Ingelheim, Menarini, Eli-Lilly, MSD, Novo Nordisk, Alfasigma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical statement is no needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}